Just Earth News | @justearthnews | 22 Sep 2020, 05:55 am Print
Moscow/Sputnik: Around 2,500 volunteers have received the first component of Russia's COVID-19 vaccine during the post-registration trials, and no significant complications have been registered, the head of the Gamaleya Research Institute of Epidemiology and Microbiology said on Tuesday.
On August 11, Russia became the first country in the world to register a vaccine against COVID-19. The vaccine, dubbed Sputnik V, was developed by the Gamaleya Institute.
"Around 2,500 Moscow residents have received the first component of the vaccine. We have not recorded any complications, apart from some minor ones, which are described in the manual," Alexander Gintsburg said at a roundtable on COVID-19.
As many as 40,000 volunteers are taking part in Phase 3 of the clinical trials, Gintsburg specified.
"The trial batches of Gamaleya's COVID-19 vaccine have been delivered to all the regions in Russia," Gintsburg told Sputnik.
Image: Pixabay
- Warning: Heavy smartphone use tied to body dissatisfaction and disordered eating
- Silent killer rising: Young women face surge in heart disease deaths
- Morning fitness secret: Why early risers are healthier, says study
- New study finds low to moderate wine consumption shows lower risk compared with spirits, beer and cider
- Hidden danger? Type 1 diabetes linked to much higher dementia risk than expected
-1763561110.jpg "Image of the day: November 19, 2025")